Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression by Roth, Carina et al.
RESEARCH ARTICLE Open Access
Apoptosis-related deregulation of proteolytic
activities and high serum levels of circulating
nucleosomes and DNA in blood correlate with
breast cancer progression
Carina Roth
1, Klaus Pantel
1, Volkmar Müller
2, Brigitte Rack
3, Sabine Kasimir-Bauer
4, Wolfgang Janni
5,
Heidi Schwarzenbach
1*
Abstract
Background: As cell-free circulating DNA exists predominantly as mono- and oligonucleosomes, the focus of the
current study was to examine the interplay of circulating nucleosomes, DNA, proteases and caspases in blood of
patients with benign and malignant breast diseases.
Methods: The concentrations of cell-free DNA and nucleosomes as well as the protease and caspase activities
were measured in serum of patients with benign breast disease (n = 20), primary breast cancer (M0, n = 31),
metastatic breast cancer (M1, n = 32), and healthy individuals (n = 28) by PicoGreen, Cell Death Detection ELISA,
Protease Fluorescent Detection Kit and Caspase-Glo
®3/7 Assay, respectively.
Results: Patients with benign and malignant tumors had significantly higher levels of circulating nucleic acids in
their blood than healthy individuals (p = 0.001, p = 0.0001), whereas these levels could not discriminate between
benign and malignant lesions. Our analyses of all serum samples revealed significant correlations of circulating
nucleosome with DNA concentrations (p = 0.001), nucleosome concentrations with caspase activities (p = 0.008),
and caspase with protease activities (p = 0.0001). High serum levels of protease and caspase activities associated
with advanced tumor stages (p = 0.009). Patients with lymph node-positive breast cancer had significantly higher
nucleosome levels in their blood than node-negative patients (p = 0.004). The presence of distant metastases
associated with a significant increase in serum nucleosome (p = 0.01) and DNA levels (p = 0.04), and protease
activities (p = 0.008).
Conclusion: Our findings demonstrate that high circulating nucleic acid concentrations in blood are no indicators
of a malignant breast tumor. However, the observed changes in apoptosis-related deregulation of proteolytic
activities along with the elevated serum levels of nucleosomes and DNA in blood are linked to breast cancer
progression.
Background
Every year, more than one million women are world-
wide diagnosed with breast cancer, the second most
common tumor entity after lung cancer. At the time of
initial diagnosis approximately 5% of patients are found
to have advanced or metastatic disease [1]. Although
screening techniques, surgical and radiotherapy inter-
ventions of breast cancer patients have improved the
curative rate, a certain percentage of women will
develop recurrent or metastatic disease after adjuvant
treatment [2]. Therefore, the development of a preo-
perative blood test that is able to detect early breast
tumors and determine regional lymph node or distant
metastasis would be desirable.
The quantification of cell-free DNA, which circulates
in high concentrations in blood of patients with various
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non-invasive test. The mechanism of DNA release into
the blood circulation occurs either by proliferating or
dying cells, such as apoptotic and necrotic cells [4]. It is
supposed that this DNA circulates preferentially as
mono- and oligonucleosomes. As a late event of apopto-
sis, intracellular endonucleases, such as caspase-activated
DNases, are induced and cleave chromatin at the easily
accessible internucleosomal linker regions into mono-
or oligonucleosomes [5]. Dying cells are usually phago-
cytosed by macrophages, but an excess of cell death
leads to saturation of this process and to elevated levels
of fragmented nucleosomal DNA in the blood circula-
tion [6]. As nucleosomes are rapidly degraded and
hydrolyzed from the blood circulation by DNases and
proteases, their half life in blood seems to be short [7].
The elevated levels of circulating DNA in blood of
cancer patients have been shown to reflect the charac-
teristics of tumor DNA, and to harbor genetic and epi-
genetic alterations [3]. Previously, we demonstrated the
potential of circulating tumor-associated DNA in blood
for molecular diagnosis and its prognostic value to iden-
tify breast cancer patients at high risk for relapse [8-11].
Accordingly, circulating nucleosomes in blood may also
provide an indication of tumor DNA. Although numer-
ous studies focused on the quantification of circulating
DNA, only some studies have analyzed the clinical rele-
vance of circulating nucleosomes for diagnosis and
prognosis [12-16]. As compared with healthy controls
increased concentrations of circulating nucleosomes
were measured in various tumor entities [12], but only
two studies dealt on breast cancer [17,18].
An essential aspect for cancer development and pro-
gression is the deregulation of caspases involved in the
regulated apoptotic cascade which consequently, leads
to the release of DNA or nucleosomes into the blood
circulation [19]. Caspases are cysteine proteases belong-
ing to a large family which constitutes of serine, aspartic
and metallo proteases. Proteases may promote cancer
progression, because they degrade the extracellular
matrix and facilitate subsequent invasion of tumor cells
into the surrounding normal tissue. As a result of the
aberrantly activated signal transduction in tumors, these
enzymes are frequently overexpressed in various cancer
entities. The prevailing acceptance that proteases are
involved in metastasis led to the development of small-
molecule inhibitors for the treatment of cancer [20].
T h ea i mo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t et h e
influence of protease and caspase activities on the levels
of circulating nucleosomes and DNA in blood of breast
cancer patients, and to correlate the obtained data with
the clinicopathological parameters of these patients.
Despite the small sample sizes of the cohorts, the broad
range of preliminary results shows that the quantification
of these determinants could be used as a rapid, non-
invasive and blood-based screening tool for the early
detection of breast tumor progression.
Methods
Tumor patients and healthy volunteers
The present study was conducted at the Clinic of Gynecol-
ogy of the University Medical Center Hamburg-Eppen-
dorf, at the Ludwig Maximilians University of Munich and
at the Department of Gynecology and Obstetrics of the
University Hospital of Essen. Between April 2006 and
September 2008 blood serum was obtained from 20
patients with benign breast disease (University Hospital of
Essen). During January 2008 to August 2009, blood serum
was taken from 31 patients with primary breast cancer
(M0) after surgery before initiation of adjuvant therapy
(Ludwig Maximilians University of Munich). During Janu-
ary to April 2009, blood serum from 32 patients with
metastatic breast cancer (M1) was collected 1 to 13 years
after surgery of the primary tumor (University Medical
Center Hamburg-Eppendorf). Additionally, 28 female con-
trols aged between 21 and 67 with no history of cancer
were recruited. The median ages of patients with benign
and malignant breast disease was 49 (range 18-79) and
56 (range 34-82), respectively. The data of the tumor
patients and healthy controls are summarized in Table 1.
Informed written consent was obtained from all dis-
eased and healthy individuals, and the study was
approved by the Local Research Ethics Committee.
Quantification of circulating cell-free DNA and
nucleosomes in blood serum
For quantification of the relative amounts of cell-free
DNA and nucleosomes in serum, the Quant-iT Pico-
Green dsDNA Kit (Invitrogen, Karlsruhe, Germany) and
the Cell Death Detection ELISA plus kit (Roche Diagnos-
tics, Mannheim, Germany) were performed, respectively,
and carried out according to the manufacturer’s protocol.
Quantification of the protease activity in blood serum
For quantification of the relative protease activity, the
Protease Fluorescent Detection Kit (Sigma-Aldrich,
Taufkirchen, Germany) was used, and carried out
according to the manufacturer’s protocol. This kit is
based on the proteolytical hydrolysis of a Fluorescein
Isothiocyanat (FITC)-labeled casein-substrate detecting
all four proteases (serine, aspartic, cysteine and metallo
proteases). A three-point standard curve of 1:10, 1:20
and 1:40 dilutions of Trypsin Control was prepared.
Quantification of the activities of caspases 3 and 7 in
blood serum
For measurements of the activities of caspases 3 and 7,
the Caspase-Glo
®3/7 Assay (Promega, Mannheim,
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Page 2 of 12Table 1 Patient characteristics and their correlations with the nucleic acid levels and protease/caspase
activities in blood
Patients (%) Nucleosome levels DNA levels Protease activities Caspase activities
Mean values ± Standard Deviation
Median
Percentiles (10
th,9 0
th)
Breast Cancer Patients
Total 63
Age 56 years (range 34 - 82 years)
Distant metastasis
£M0 31 (49.2)
1 878 ± 123
851
767, 1078
2 8241 ± 701
8293
7232, 9195
3 22218 ± 12236
12682
10401, 35242
35895 ± 62242
7990
2550, 134240
$M1 32 (50.8)
1 894 ± 112
841
812, 1076
2 9933 ± 4430
8756
7237, 16836
3 32337 ± 9021
33326
13573, 45296
11486 ± 9167
8570
4718, 31628
#Tumor stage
pT1-2 29 (53.7) 866 ± 31
858
822, 1058
8352 ± 728
8528
6559, 10246
4 11042 ± 750
10966
10412, 41664
5 5386 ± 2042
5545
2655, 24540
pT3-4 25 (46.3) 829 ± 125
769
763, 1079
7690 ± 389
7564
7240, 19519
4 30439 ± 10052
34378
12258, 42790
5 66341 ± 93967
26670
2736, 181806
#Lymph node metastasis
N0 13 (23.6)
6 814 ± 80
769
767, -
8027 ± 518
8011
7517, -
26649 ± 14005
34216
10488, -
19370 ± 17547
12350
6420, -
N1-3 42 (76.4)
6 860 ± 85
844
781, 1079
8079 ± 737
8149
6901, 10904
17366 ± 10972
11167
10408, 43572
34821 ± 74658
6890
2613, 66132
#Grading
I-II 25 (46.3) 813 ± 39
827
762, 1057
7914 ± 896
7885
6807, 9056
18737 ± 11916
11964
10001, 37741
47295 ± 99075
7570
2544, 225815
III 29 (53.7) 878 ± 98
878
768, 1118
8183 ± 494
8137
6984, 15827
19819 ± 12451
11165
10469, 39564
19671 ± 27313
6655
2907, 51685
#Estrogen receptor
positive 41 (68.3) 846 ± 92
837
767, 1078
7924 ± 719
7868
7185, 9298
20468 ± 12204
11964
10356, 45976
38382 ± 77766
7570
2547, 97376
negative 19 (31.7) 861 ± 65
885
767, -
8428 ± 445
8351
6357, -
16574 ± 11766
10827
10423, -
14330 ± 16701
6655
4670, -
#Progesterone receptor
positive 36 (60) 825 ± 44
830
768, 1010
7927 ± 796
8124
6949, 9039
17617 ± 11811
11163
10135, 46261
7317 ± 4533
7152
2532, 25178
negative 24 (40) 875 ± 107
865
764, 1144
8209 ± 561
8149
6805, 18757
21094 ± 12382
12682
10456, 35961
55703 ± 90000
6890
2910, 164920
#HER2
positive 23 (39.7) 855 ± 88
844
767, 1078
8148 ± 628
8149
7249, 9183
19548 ± 11973
11167
10312, 39775
35294 ± 74482
6890
2544, 114262
negative 35 (60.3) 832 ± 70
823
772, 1193
7774 ± 919
8011
6397, 24618
18650 ± 13486
11245
10564, 45011
17637 ± 18799
7150
4765, 38669
Benign Breast Tumor Patients
Total 20
Age 49 years (range 18 - 79 years)
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turer’s instructions. This kit is based on the cleavage of
the DEVD sequence of a luminogenic substrate by the
caspases 3 and 7 resulting in a luminescent signal.
Statistical analyses
The statistical analyses were performed using the SPSS
software package, version 18.0 (SPSS Inc. Chicago, IL).
The chi Square or two-tailed Fischer’se x a c tt e s tw a s
used to identify possible associations of the measured
parameters. For non parametric comparisons, univariate
analyses of the Mann Whitney-U test and the T test of
two independent variables, and bivariate analyses of the
Spearman’s rank correlation were performed. Diagnostic
power of the single markers was analysed by receiver
operating characteristic (ROC) curves. Areas under the
curves (AUC) were calculated. A p-value ≤ 0.05 was
considered as statistically significant. All p-values are
two-sided.
Results
Quantification of circulating nucleosomes and DNA in
serum
We compared the levels of circulating nucleosomes
(Figure 1) and DNA (Figure 2) in blood serum of 28
healthy individuals, 20 patients with benign breast
Table 1 Patient characteristics and their correlations with the nucleic acid levels and protease/caspase
activities in blood (Continued)
831 ± 102
794
768, 922
9306 ± 1156
8837
7611, 11240
16837 ± 5295
14845
14697, 30293
5580 ± 4186
4610
2714, 9307
Leukocytes
<10.7/nl 16 (80) 808 ± 61
788
768, -
9471 ± 1068
9191
8496, -
18044 ± 6780
15016
14689, -
4957 ± 2485
4550
2710, -
>10.7/nl 1 (5) 1228
-
-, -
11626
-
-, -
-
-
-, -
3010
-
-, -
CRP
<0.5 mg/dl 11 (55) 780 ± 16
780
768, -
9191 ± 235
9191
9024, -
24387 ± 10441
24387
17004, -
5835 ± 4363
5835
2750, -
>0.5 mg/dl 5 (25) 823 ± 72
795
772, -
9611 ± 1343
9281
8496, -
14873 ± 197
14831
14689, -
4518 ± 1782
4550
2710, -
CEA
<3.5 ng/ml 15 (75) 815 ± 65
791
768, -
9383 ± 1169
9024
8496, -
18715 ± 7354
15141
14771, -
5292 ± 2622
5820
2710, -
>3.5 ng/ml 1 (5) 772
-
-, -
9913
-
-, -
14689
-
-, -
3280
-
-, -
CA-125
<65 U/ml 15 (75) 808 ± 61
788
768, -
9471 ± 1068
9191
8496, -
18044 ± 6780
15016
14689, -
4957 ± 2485
4550
2710, -
>65 U/ml 2 (10) 1011 ± 307
-
-, -
9926 ± 2404
-
-, -
14799
-
-, -
3735 ± 1025
-
-, -
Healthy Women
Total 28
Age 41 years (range 21 - 67 years)
726 ± 50
725
715, 809
7747 ± 678
7641
7175, 8801
21133 ± 8028
14996
13166, 30500
5182 ± 2379
5075
3064, 9277
£M0, patients with localized breast cancer.
$M1, patients with metastatic breast cancer.
#parameters of M0 patients.
1p = 0.01,
2p = 0.04,
3p = 0.008,
4*p = 0.009,
5p = 0.009,
6p = 0.004.
p values as determined by Mann and Whitney-U test (in bold).
*p values as determined by T test (in bold).
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metastatic breast cancer (M1) patients.
As shown in the box plots of Figure 1A, healthy indi-
viduals displayed significantly lower nucleosome levels
in their blood than patients with benign and malignant
breast lesions (p = 0.0001). As determined by univariate
analyses of the Mann Whitney-U test, the nucleosome
concentrations in blood of M1 patients were higher
than those of patients with benign disease and M0
patients (p = 0.01, Table 1) who had similar concentra-
tions (Figure 1A). In order to determine the sensitivity
and specificity of the circulating nucleosomes in distin-
guishing healthy controls from breast cancer patients
(Figure 1B), benign tumor patients from breast cancer
patients (Figure 1C) and M0 from M1 breast cancer
patients (Figure 1D), we performed ROC analyses and
used area under the ROC curve (AUC) to test its perfor-
mance. The AUC values were between 0.629 and 0.934,
demonstrating the significant differences of the nucleo-
some levels (Figure 1).
As shown in the box plots of Figure 2A, healthy indi-
viduals also displayed significantly lower DNA concen-
trations in their blood than patients with benign (p =
0.0001) and malignant (p = 0.001) breast lesions. Sur-
prisingly, high serum levels of DNA could be detected
in patients with benign breast disease. Patients with
benign breast tumor had the highest levels, and M1
patients had higher levels than M0 patients (p = 0.04,
Table 1). In order to determine the sensitivity and speci-
ficity of the cell-free DNA in distinguishing healthy con-
trols from breast cancer patients (Figure 2B), benign
tumor patients from breast cancer patients (Figure 2C)
and M0 from M1 breast cancer patients (Figure 2D), we
performed ROC analyses. The AUC values were
between 0.249 and 0.769 (Figure 2).
A ss h o w ni nas c a t t e rp l o to fF i g u r e3 ,t h eb i v a r i a t e
statistical analysis of the serum samples of all patients
and healthy individuals revealed a significant correlation
between nucleosome and DNA concentrations (p =
0.001, r = 0.327; Spearman rank test).
Quantification of protease and caspase activities
in blood serum
To determine the impact of protease and caspase activ-
ities on the levels of circulating nucleosomes and DNA,
we measured these activities in blood serum of the
patient subgroups and healthy individuals (Figures 4
and 5). The protease assay was optimized for measuring
the activities of serine, cysteine, metallo and aspartic
proteases (Figure 4). In addition, we also separately
measured the activities of caspases 3 and 7 (Figure 5),
because they play key effecter roles in apoptosis leading
to the release of nucleosomes or DNA into the blood
circulation.
In contrast to benign breast tumor and M1 patients, a
broad range of protease activities was observed in
healthy individuals and M0 patients (Figure 4A). In M1
patients the median levels of serum protease activities
was approximately 2-2.5-fold higher than in the other
subgroups. In order to determine the sensitivity and
specificity of the relative protease activities in distin-
guishing healthy controls from breast cancer patients
(Figure 4B), benign tumor patients from breast cancer
patients (Figure 4C) and M0 from M1 breast cancer
patients (Figure 4D), we performed ROC analyses. The
AUC values were >0.642 (Figure 4).
As shown in Figure 5A, both subgroups M0 and M1
had 1.7-fold higher median levels of serum caspase
activities than healthy controls and patients with benign
breast disease. The AUC values of ROC analyses were
between 0.451 and 0.786 (Figure 5B-D).
The Spearman rank test of all analyzed blood samples
revealed significant correlations between the circulating
nucleosome levels and caspase activities (p = 0.008, r =
0.268; Figure 6A), and between the protease and caspase
activities (p = 0.0001, r = 0.539; Figure 6B).
Clinical relevance of circulating nucleosomes, DNA,
proteases and caspases in blood serum
Statistical evaluations of the circulating nucleosome and
DNA concentrations as well as protease and caspase activ-
ities in blood of 31 M0 and 32 M1 patients were per-
formed with their clinical and histopathological data
(Table 1). Significant associations of the elevated serum
protease and caspase activities with advanced tumor stages
could be observed in M0 patients (p = 0.009). Eighty-five
% of women with pT1-2 and 72% of women with pT3-4
had low and high protease activity levels, respectively.
Moreover, 82% of patients with pT1-2 and 55% of patients
with pT3-4 had low and high caspase levels, respectively.
In addition, upregulated protease activities correlated with
distant metastases of the cancer patients (p = 0.008).
Increasing levels of circulating nucleosomes associated
with lymph node metastases (p = 0.004) and distant
metastases (p = 0.01), whereas circulating serum DNA
associated with the presence of overt metastases in the
breast cancer patients (p = 0.04, Table 1).
Statistical evaluations of the circulating nucleosome
and DNA concentrations as well as protease and caspase
activities in blood of benign breast tumor patients could
not be performed with the lab parameters of these
patients, because this patient cohort (n = 20) was too
small and the distribution of patients within the popula-
tions with high and low values was too heterogeneous
(Table 1). Of the 20 patients there was only one patient
who had simultaneously very pronounced leukocyte,
CRP (C-reactive protein) and CA125 values. This patient
had also high nucleosome and DNA values.
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In the current study we examined the relationship of the
serum levels of circulating nucleic acids with the activ-
ities of proteases and caspases. In addition, we explored
the interplay and the changes in release of these deter-
minants in the blood circulation of breast cancer
patients, patients with benign breast disease and healthy
individuals.
Although patients with benign and malignant breast
tumors had significantly higher levels of circulating
nucleosomes and DNA in their blood than healthy indi-
viduals, these elevated yields could not discriminate
between benign and malignant lesions as documented
by our present study. Thus, cell-free nucleic acids may
be a molecular biomarker for detecting both, benign
and malignant breast diseases in contrast to the circulat-
ing protease and caspase activities which were specifi-
cally increased in blood of breast cancer patients.
Cell-free DNA may circulate in human blood in
diverse forms, as naked DNA, associated with histones
as nucleosomes, bound to other plasma proteins or
packed in apoptotic bodies [12]. Our detection of the
significant association of nucleosome concentrations
with DNA concentrations in blood of all patients and
healthy individuals emphasized that DNA may predomi-
nantly circulate in form of nucleosomes in human
blood. A major mechanism underlying the release
of nucleosomes into the blood circulation is the
Breast Tumors
p=0.0001
p=0.0001
p=0.0001
p=0.01
A
Healthy vs. Cancer
AUC=0.934
(95% CI: 0.883-0.985)
D C
B
Benign vs. Malignant Tumor 
AUC=0.629
(95% CI: 0.496-0.761)
M0 vs. M1 Cancer
AUC=0.679
(95% CI: 0.540-0.819)
Figure 1 Comparative analyses of circulating nucleosomes in blood of tumor patients and healthy individuals. The box plots compare
the circulating nucleosome concentrations of healthy individuals (n = 28) with those of patients with benign breast disease (n = 20), primary
breast cancer (M0, n = 31) and metastatic breast cancer (M1, n = 32) (A). The statistical significances of these comparative analyses, as
determined by the Mann and Whitney-U test for the non parametric comparison of two independent variables, are indicated. The ROC analyses
show the profiles of sensitivity and specificity of nucleosome concentrations to discriminate healthy controls from breast cancer patients (B),
benign tumor patients from breast cancer patients (C) and M0 from M1 breast cancer patients (D).
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oligonucleosomal fragments by activated endonucleases.
In this apoptotic process caspases play a central role
inducing nucleosomal DNA fragmentation by activating
DNases. In malignant tumors the apoptotic cell death
seems to be increased [21]. As shown by our current
findings, the activities of caspases 3 and 7 were signifi-
cantly upregulated in blood of breast cancer patients in
comparison to patients with benign breast disease and
healthy individuals, and these increased activities were
associated with advanced tumor stages. In particular,
our data suggest that in breast cancer patients caspases
3 and 7 are involved in apoptosis which may lead to the
excess of circulating nucleosomes in blood of these
patients. Additionally, our detection of the upregulation
of caspases 3 and 7 in advanced tumor stages may
reflect their active role in tumor progression. As demon-
strated by immunohistochemical analyses in another
study, the caspases 6 and 8, besides the caspase 3, may
also be engaged in the apoptosis of breast carcinomas as
well as preneoplastic lesions. The expression of these
caspases, which was strongly associated with an
increased apoptotic index, was significantly lower in
benign epithelial hyperplasias than in situ carcinomas
and invasive carcinomas [22]. Accordingly, we found no
increase in the activities of caspases 3 and 7 in the
blood serum of patients with benign disease, but an
association of their activities with the concentrations of
circulating nucleosomes in all patients. This indicates
that apart from caspases 3 and 7, other caspases may
A
p=0.0001
Breast Tumors
p=0.001
p=0.001
p=0.04
D C
B
Healthy vs. Cancer
AUC=0.769
(95% CI: 0.652-0.886)
M0 vs. M1 Cancer
AUC=0.649
(95% CI: 0.510-0.789)
Benign vs. Malignant Tumor
AUC=0.249
(95% CI: 0.129-0.369)
Figure 2 Comparative analyses of cell-free DNA in blood of tumor patients and healthy individuals. The box plots compare the
circulating DNA concentrations of healthy individuals (n = 28) with those of patients with benign breast disease (n = 20), primary breast cancer
(M0, n = 31) and metastatic breast cancer (M1, n = 32) (A). The statistical significances as determined by the Mann and Whitney-U test are
indicated. The ROC analyses show the profiles of sensitivity and specificity of DNA concentrations to discriminate healthy controls from breast
cancer patients (B), benign tumor patients from breast cancer patients (C) and M0 from M1 breast cancer patients (D).
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patients with benign breast disease. In contrast to our
data, Deligezer et al. obtained no correlation of nucleo-
somal DNA fragmentation with the occurrence of
caspases in patients with lymphoma and myeloma. The
reason of this discrepancy is that they did not analyze
the activities of the circulating serum caspases 3 and 7,
but only the yields of caspase-3 transcripts in
lymphocytes [23].
Besides the elevation of caspase activities, we also
observed a significant upregulation of protease activities,
including the various serine, cysteine, metallo and aspar-
tic proteases, in blood of patients with advanced tumor
stages and metastatic disease. Our findings substantiate
the active role of proteases in tumor progression and
metastases. The degradation of extracellular matrix
represents a key event in the multistage process of
tumor invasion and metastasis. Such a degradation
requires the concerted action of proteases which are
involved in the proteolysis of many different compo-
nents of the extracellular matrix [24]. The cleavage of
extracellular matrix proteins has also been related to tis-
sue remodeling and neo-vascularization [25]. These pro-
cesses support the dissemination of tumor cells into the
blood circulation [26,27]. The apoptosis of these cells
may also contribute to the elevated levels of nucleic
acids in blood [11,28]. In contrast to the high protease
activities in breast cancer patients, we found that these
activities in blood of patients with benign disease were
not increased, endorsing that proteases, as well as the
caspases 3 and 7, seem to play a smaller role in benign
than in malignant lesions. In particular, the matrix
metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs) are thought to be involved
in tumor progression and metastasis [29,30]. Consistent
to our results on the protease activities, Wu et al. found
Figure 3 Significant association between nucleosome and DNA concentrations. The scatter plot of relative nucleosome vs. DNA
concentrations of serum samples from all patients and healthy individuals analyzed shows the distribution of most points on the left corner of
the diagram. The relationship of the both variables was significant (Spearman rank test).
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Page 8 of 12that serum levels of MMP-9 and TIMP-1 were signifi-
cantly higher in breast cancer patients than in benign
breast disease and healthy controls, and that they asso-
ciated with tumor progression [31].
Our data suggest that the measurement of circulating
nucleosome concentrations may be used for the risk
assessment of breast cancer patients who develop metas-
tases, because the elevated nucleosome levels signifi-
cantly associated with regional and distant metastatic
breast disease spreading. However, to sustain the prog-
nostic relevance and the clinical utility of serum nucleo-
somes, as well as DNA, long-term follow-up analyses
have to be performed.
Although we found significantly higher nucleosome
levels in blood of lymph node-positive and metastatic
breast cancer patients than in patients without overt
metastases or with benign breast disease, serum DNA
yields were lower in cancer patients than in patients
with benign breast disease. However, we detected a sig-
nificant association between the DNA and nucleosome
values of all patients and healthy individuals. This osten-
sible discrepancy can be explained by the dramatic
increase in the nucleic acids in blood of patients with
benign disease. Nevertheless, the rise in nucleosome and
DNA levels leading from healthy individuals over M0
patients to M1 patients was similar, albeit the inclina-
tion of the DNA levels of these three cohorts was some-
what more gently than that of the nucleosome levels.
Why the DNA and nucleosome concentrations are so
high in our cohort of patients with benign disease is
Breast Tumors
p=0.0001
p=0.008
p=0.0001
A
D
B
Healthy vs. Cancer
AUC=0.688
(95% CI: 0.547-0.828)
M0 vs. M1 Cancer
AUC=0.643
(95% CI: 0.458-0.827)
C
Benign vs. Malignant Tumor
AUC=0.688
(95% CI: 0.546-0.829)
Figure 4 Comparative analyses of circulating protease activities in blood of tumor patients and healthy individuals.T h eb o xp l o t s
compare the relative protease activities in blood of healthy individuals (n = 28) with those of patients with benign breast disease (n = 20),
primary breast cancer (M0, n = 31) and metastatic breast cancer (M1, n = 32) (A). The statistical significances as determined by the Mann and
Whitney-U test are indicated. The ROC analyses show the profiles of sensitivity and specificity of protease activities to discriminate healthy
controls from breast cancer patients (B), benign tumor patients from breast cancer patients (C) and M0 from M1 breast cancer patients (D).
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Page 9 of 12unknown. It is well-known that an increased amount of
circulating DNA is not only related to cancer, but is
also found in blood of patients with severe inflammatory
processes [32]. Since also carcinomas are associated with
inflammatory processes, these high DNA levels in
patients with benign breast disease are anyhow surpris-
ing. However, a previous study showed results alike to
ours, indicating that serum levels of circulating cell-free
DNA could have diagnostic value to discriminate
between healthy individuals and patients with breast
lesions, but they have no relevance to discriminate
between patients with malignant and benign breast
lesions [33]. In addition, Holdenrieder et al. also
detected elevated serum levels of nucleosomes in various
benign diseases, particularly in infectious diseases, and
showed that the quantification of nucleosomes limits
the diagnostic capacity for cancer detection [12]. Nucleic
acids may be released into the blood circulation by
damaged cells which are present in both, benign and
malignant diseases. A factor for these high serum con-
centrations in patients with benign breast tumors could
be the delayed clearance of nucleic acids. We tried to
determine the DNase activity in the different cohorts,
but the measured values were too low to evaluate them.
Therefore, we do not know whether the DNA concen-
trations inversely correlate with DNase levels. However,
that DNA is an remarkably robust molecule and resis-
tant against degradation was demonstrated in mice in
whom orally ingested DNA survived the digestion in the
gastrointestinal tract [34].
A
p=0.0001
p=0.008
p=0.0001
p=0.01
Breast Tumors
D
B
Healthy vs. Cancer
AUC=0.774
(95% CI: 0.669-0.879)
M0 vs. M1 Cancer
AUC=0.451
(95% CI: 0.259-0.643)
C
Benign vs. Malignant Tumor
AUC=0.786
(95% CI: 0.666-0.906)
Figure 5 Comparative analyses of circulating caspase activities in blood of tumor patients and healthy individuals.T h eb o xp l o t s
compare the relative caspase activities in blood of healthy individuals (n = 28) with those of patients with benign breast disease (n = 20),
primary breast cancer (M0, n = 31) and metastatic breast cancer (M1, n = 32) (A). The statistical significances as determined by the Mann and
Whitney-U test are indicated. The ROC analyses show the profiles of sensitivity and specificity of caspase activities to discriminate healthy
controls from breast cancer patients (B), benign tumor patients from breast cancer patients (C) and M0 from M1 breast cancer patients (D).
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Page 10 of 12In breast cancer the serum tumor markers cancer
antigen (CA) 15-3 and carcinoembryonic antigen (CEA)
play a role in tumor growth and spreading. Particularly
in advanced stages of cancer patients these markers
have been shown to be elevated [35]. While in patients
with primary breast cancer the concentration of CA
15-3 and CEA are usually within the normal range,
increased levels are often observed in patients with
metastatic disease, and correlate with increased meta-
static load [36]. Moreover, it has been reported that
serum nucleosomes showed a significant positive corre-
lation with CA 15-3 in breast cancer patients [37].
Therefore, it would be interesting to investigate whether
our data on nucleic acid concentrations and proteolytic
activities refer to these protein markers. Since in our
breast cancer cohort CA 15-3 was not recorded, and
CEA was measured in only 19 patients, a statistical
comparison was not possible. Studies which implicate
these markers are planned in the future.
Conclusion
In conclusion, based on the significant association between
DNA and nucleosomes, DNA may predominantly circulate
in form of nucleosomes in human blood. Although serum
levels of nucleosomes and DNA in breast cancer patients
are significantly elevated when compared with healthy con-
trols, they are not useful for cancer diagnosis, owing to the
increase in blood of patients with benign breast tumors.
Nevertheless, the quantification of circulating nucleic acids
as a rapid, non-invasive and blood-based screening tool
could be used for the early detection of breast tumor pro-
gression, but larger studies with follow-up blood samples
are required to corroborate this conclusion. The increased
activities of caspases 3 and 7 observed in blood of the
patients with advanced tumor stages and metastatic disease
may contribute to the rise in nucleic acid concentrations in
blood of cancer patients, but they do not seem to be rele-
vant for the high serum levels of nucleic acids in patients
with benign breast disease. Here, other caspases seem to be
responsible for this release. The striking upregulation of
the protease activities in patients with advanced tumor
stages and metastatic disease reflects their role in tumor
progression and metastases.
Considering the small sample sizes of our cohorts and
the broad range of our data, additional studies to these
preliminary results are warranted to obtain further
information on the tumor activity and to determine the
clinical relevance of the circulating nucleic acids in
blood of breast cancer patients.
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